NAFLD / MASLD and Alcohol, Caffeine, and Cannabis: What the Evidence Shows

What Is MASLD and Why Do Substances Matter?

Metabolic-associated steatotic liver disease (MASLD) is the 2023 multi-society renaming of what was previously called non-alcoholic fatty liver disease (NAFLD). The new name requires at least one cardiometabolic risk factor and alcohol consumption below defined thresholds (less than 140 g/week for men, less than 70 g/week for women) to distinguish it from alcohol-associated liver disease. MASLD affects roughly 25 to 30% of U.S. Adults, making it the most common chronic liver condition in the country [1].

Every psychoactive substance a patient consumes, including alcohol, caffeine, and cannabis, reaches the liver through the portal circulation before it reaches systemic blood. That anatomical reality means the liver is the first organ to face the chemical burden, and in a liver already storing excess fat, the margin for added stress is narrower than in a healthy organ.

The MASLD Diagnostic Criteria

The 2023 multi-society nomenclature consensus, published in journals including Hepatology and Journal of Hepatology, established that MASLD requires hepatic steatosis plus at least one of the following: BMI above 25 kg/m², fasting glucose at or above 100 mg/dL, blood pressure at or above 130/85 mmHg, triglycerides at or above 150 mg/dL, or HDL below 40 mg/dL in men (below 50 mg/dL in women) [2]. Patients who exceed the alcohol thresholds above are reclassified as having metabolic and alcohol-related liver disease (MetALD) or alcohol-associated liver disease (ALD).

Why Lifestyle Modifications Are First-Line

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance states that weight reduction of 7 to 10% body weight through diet and physical activity is the most evidence-based intervention for resolving steatohepatitis and reducing fibrosis [3]. No drug replaces lifestyle modification, and the substances reviewed in this article either actively sabotage that goal or, in the case of coffee, appear to support it.

Alcohol in NAFLD / MASLD: No Truly Safe Dose

Alcohol is uniquely hepatotoxic in the setting of existing steatosis. Even quantities that would be considered "light drinking" in a metabolically healthy person may accelerate fibrosis in someone with MASLD.

What the Epidemiological Data Show

A 2021 meta-analysis of 10 prospective cohort studies (N = 458,927) published in Hepatology found that any alcohol consumption above 0 g/day was associated with a dose-dependent increase in all-cause liver mortality among people with pre-existing hepatic steatosis [4]. The hazard ratio for liver-related mortality with moderate drinking (14 to 28 g/day) versus abstinence was 1.45 (95% CI 1.18 to 1.77). Light drinking showed a smaller but still elevated risk (HR 1.14).

A separate UK Biobank analysis (N = 111,613) reported that individuals with metabolic risk factors who drank even within national "low-risk" limits (less than 14 units/week in the UK) had significantly higher odds of advanced fibrosis on FIB-4 scoring compared with abstainers [5].

Mechanistic Pathways

Alcohol metabolism generates acetaldehyde and reactive oxygen species. In a liver already experiencing lipotoxicity from excess free fatty acids, this additional oxidative load activates Kupffer cells, promotes nuclear factor-kappa B (NF-kB) signaling, and accelerates stellate cell-driven fibrogenesis. Alcohol also impairs mitochondrial beta-oxidation, the same pathway already compromised in MASLD, creating a compounding deficit in fat clearance.

What the Guidelines Recommend

The AASLD 2023 practice guidance explicitly advises patients with MASLD to avoid alcohol, or limit intake to the lowest possible amount. The guidance notes: "Given the lack of a defined safe threshold, abstinence from alcohol is the most prudent recommendation for patients with established MASH or significant fibrosis (F2 or higher)" [3].

The European Association for the Study of the Liver (EASL) 2024 clinical practice guidelines echo this position, stating that alcohol consumption "even at low doses contributes to fibrosis progression in MASLD and should be discouraged" [6].

Practically speaking, if a patient with MASLD chooses not to abstain, current clinical consensus suggests staying below one standard drink per day (approximately 14 g of ethanol) and avoiding binge episodes entirely. This is a ceiling, not a target.

Caffeine and Coffee: The One Substance With Consistent Benefit

Coffee is the most studied dietary substance in liver disease research, and the evidence is more consistent here than in most other areas of hepatology.

Meta-Analytic Evidence on Fibrosis and Steatosis

A 2017 meta-analysis of 9 observational studies (N = 430,000+) found that consuming 2 or more cups of coffee per day was associated with a 44% lower risk of liver cirrhosis compared with no coffee consumption [7]. A second meta-analysis specifically focused on NAFLD and published in European Journal of Nutrition (2021, 16 studies, N = 219,878) found that habitual coffee consumption (3 or more cups/day) was associated with a 39% lower odds of NAFLD diagnosis (OR 0.61, 95% CI 0.50 to 0.75) [8].

Dose matters. Most benefit in the data clusters at 3 cups per day or above. Decaffeinated coffee shows a smaller but still measurable benefit, suggesting both caffeinated and non-caffeinated compounds contribute.

The Biochemical Mechanisms

Caffeine inhibits hepatic stellate cell activation through adenosine receptor antagonism, specifically the A2A receptor, reducing TGF-beta1-driven collagen deposition [9]. Coffee also contains chlorogenic acids and other polyphenols that reduce oxidative stress and hepatic fat accumulation through AMPK activation.

A 2020 cell-culture and murine study published in Journal of Hepatology demonstrated that cafestol and kahweol (diterpenes present in unfiltered coffee such as French press or espresso) inhibited lipid accumulation in human hepatocytes at physiologically achievable concentrations [10]. Filtered drip coffee contains fewer diterpenes, but its polyphenol content still confers measurable antifibrotic signaling.

Practical Guidance for Patients

• Three to four cups of coffee daily (any preparation) appears to be the range associated with the most consistent liver benefit.
• Adding sugar or high-fat creamers may blunt metabolic benefit and worsen insulin resistance.
• Patients with anxiety disorders, hypertension, or pregnancy should weigh cardiovascular and other risks against hepatic benefit.
• Tea (green and black) shows a directionally similar but weaker and less consistent signal in available meta-analyses.

The HealthRX medical team uses a three-tier framework for counseling MASLD patients on beverages: (1) abstain from alcohol entirely or stay well below one drink per day; (2) target 3 or more cups of plain coffee daily if tolerated; (3) replace sugar-sweetened beverages with water, unsweetened tea, or black coffee as the default intervention before any pharmacotherapy discussion.

Cannabis and the Liver: A More Complex Picture

Cannabis is the most used illicit substance in the United States, with roughly 18% of adults reporting past-year use as of CDC 2023 data [11]. Its interaction with MASLD is more complicated than either alcohol or caffeine because cannabis contains multiple active compounds (primarily THC and CBD) that act on different receptor systems with opposing effects.

THC, CB1 Receptors, and Hepatic Fat

The endocannabinoid system is directly involved in hepatic lipid metabolism. CB1 receptors are expressed on hepatocytes, and activation by THC promotes de novo lipogenesis through upregulation of SREBP-1c, a key transcription factor for fatty acid synthesis. In a well-cited mouse model published in Hepatology (2008), CB1 receptor activation increased hepatic fat accumulation and worsened insulin resistance, while CB1 knockout mice were protected from diet-induced steatosis [12].

Human observational data are more mixed. A 2019 analysis of NHANES data (N = 10,601) reported that daily cannabis users had higher rates of NAFLD (OR 1.55, 95% CI 1.10 to 2.18) after adjusting for BMI, alcohol, and smoking compared with non-users [13]. The association was strongest among heavy daily users.

CBD: A Different Signal

Cannabidiol (CBD) does not bind CB1 receptors with meaningful affinity and may have modest hepatoprotective effects through antioxidant and anti-inflammatory pathways. Animal studies show CBD reduces lipopolysaccharide-induced hepatic inflammation and may attenuate fibrosis through PPARgamma agonism. Human RCT data on CBD and liver outcomes in MASLD do not yet exist at adequate power.

Patients often ask whether CBD products are safe to use with MASLD. The honest answer is that there is not enough human evidence to confirm benefit, and CBD at high doses carries its own hepatotoxicity signal (the FDA-approved CBD product Epidiolex carries a liver injury warning at doses above 20 mg/kg/day) [14].

Cannabis-Associated Hepatitis Risk

Cannabis use, particularly heavy use via combustion, increases systemic inflammation. Several case series link heavy cannabis use to cannabinoid hyperemesis syndrome, which can cause severe dehydration and acute kidney injury that complicates liver function testing. The hepatitis risk itself is low compared with alcohol, but the insulin-resistance and steatosis-promoting effects of chronic THC exposure are clinically relevant for MASLD patients.

What to Tell Patients About Cannabis

No major hepatology guideline explicitly endorses cannabis use for MASLD patients, and several, including the EASL 2024 guidelines, flag endocannabinoid system activation as a pathway that worsens steatosis [6]. Patients who use cannabis medicinally should discuss the form (oral CBD versus smoked THC) with their physician, minimize combustion-based delivery, and track changes in ALT and AST at routine monitoring visits.

How These Substances Interact With Pharmacotherapy

Patients increasingly combine lifestyle modifications with pharmacotherapy, including GLP-1 receptor agonists, and the interactions between substances and these agents matter.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) both reduce hepatic fat through caloric restriction, improved insulin sensitivity, and direct hepatic effects on lipid metabolism. In the NASH trial of semaglutide 0.4 mg daily (N = 320), 59% of patients in the semaglutide arm achieved NASH resolution without worsening fibrosis versus 17% on placebo (P<0.001) [15]. Weight loss of 10 to 15% drove most of the benefit.

Alcohol may blunt the effectiveness of GLP-1 therapy by independently stimulating hepatic fat deposition and worsening insulin resistance. Cannabis-driven appetite dysregulation (the "munchies" effect) may counter the appetite-suppressing mechanism of GLP-1 agents in some patients.

Resmetirom (Rezdiffra)

Resmetirom is a thyroid hormone receptor beta (THRbeta) agonist approved by the FDA in March 2024 for non-cirrhotic MASH with moderate to advanced fibrosis. In the MAESTRO-NASH trial (N = 966), resmetirom 100 mg achieved MASH resolution in 25.9% of patients versus 14.2% on placebo, and fibrosis improvement by at least one stage in 29.9% versus 19.9% (P<0.001) [16]. Alcohol consumption was an exclusion criterion in this trial, reinforcing the point that alcohol and pharmacotherapy for MASH do not coexist well in a clinical protocol.

Practical Lifestyle Interventions Beyond Substances

Managing MASLD naturally means addressing the full cardiometabolic picture, not just avoiding specific substances.

Diet

A Mediterranean dietary pattern consistently reduces hepatic fat in RCTs. A 6-month RCT (N = 278) published in Gut found that a Mediterranean diet reduced liver fat content by 29% compared with 17% on a low-fat diet (P = 0.038), independent of weight loss [17]. The key features are high intake of olive oil, vegetables, legumes, fish, and whole grains, combined with low intake of red meat, refined carbohydrates, and ultra-processed foods.

Fructose deserves specific attention. High-fructose corn syrup in sugar-sweetened beverages drives de novo hepatic lipogenesis at doses achievable with standard Western dietary patterns. Cutting sugar-sweetened beverages entirely is one of the highest-yield single dietary changes in MASLD management.

Exercise

Aerobic exercise at 150 to 300 minutes per week (moderate intensity) reduces liver fat even without significant weight loss, through improvements in mitochondrial function and insulin sensitivity. Resistance training adds benefit by increasing lean muscle mass and improving hepatic glucose uptake. A meta-analysis of 24 RCTs (N = 1,530) found both aerobic and resistance exercise reduced liver fat content by a mean of 3.1% absolute, with no significant difference between modalities [18].

Weight Loss Targets

The AASLD 2023 guidance sets 7% weight loss as the minimum threshold for steatohepatitis resolution in most patients, and 10% or above for meaningful fibrosis improvement [3]. These targets are achievable with behavioral interventions alone but are reached more reliably with pharmacological support when lifestyle changes prove insufficient.